LBIRD Lumibird SA

27.20USD24.80 EUR · EPA+2.27%Mkt Cap: 600.20M USDP/E: 38.75

Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates thr…

Key Statistics

Company
Market Cap600.20M USD
Enterprise Value701.76M USD
Revenue (TTM)259.32M USD
Gross Profit160.40M USD
Net Income (TTM)15.36M USD
Revenue/Share11.38 USD
Last Price27.20 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.1K
CountryFR
SectorHealthcare
IndustryDiagnostics & Research
ISINFR0000038242
Valuation
P/E (Trailing)38.75
P/E (Forward)30.37
PEG—
EV/EBITDA19.87
EV/Revenue2.71
P/S2.31
P/B2.65
EPS (TTM)0.70 USD
EPS (Forward)0.90 USD
52W Range
20.5761% of range31.48
52W High31.48 USD
52W Low20.57 USD
Profitability
Gross Margin63.99%
Oper. Margin10.64%
EBITDA Margin13.62%
Profit Margin6.13%
ROE6.79%
ROA3.27%
ROIC6.52%
ROCE7.52%
Growth
Revenue Growth5.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF31.81M USD
CapEx (TTM)17.94M USD
FCF Margin3.16%
FCF Yield1.37%
Net Debt101.56M USD
Net Debt/EBITDA2.88
Net Debt/FCF12.38
Balance Sheet
Debt/Equity0.71
Current Ratio2.49
Quick Ratio0.66
Book Value/Sh10.27 USD
Cash/Share2.89 USD
Dividends
Fwd Div Rate0.41 USD
Trail. Div Rate0.00 USD
Div. Yield1.54%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)33.86 USD
Upside (mean)+24.5%
Target Range32.90 USD – 34.55 USD
32.90+24.5% to mean34.55
# Analysts4
Ownership
Shares Out.22.07M
Float10.11M
Insiders53.58%
Institutions17.60%
Technical
SMA 5026.35 (+3.2%)
SMA 20026.57 (+2.4%)
Beta0.99
S&P 52W Chg12.00%
Avg Vol (30d)32.43K
Avg Vol (10d)34.66K
Technical Indicators
RSI (14)55.2
MACD0.2107
MACD Signal0.1784
MACD Hist.+0.0323
BB Upper27.94 USD
BB Middle26.65 USD
BB Lower25.35 USD
BB Width9.71%
ATR (14)0.8954 USD
Vol Ratio (20d)0.98x

About Lumibird (EPA: LBIRD)

›

Lumibird (EPA: LBIRD) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 1,078 employees.

The shares were at 24.80 EUR on 19 November 2026, up 27.2% over 52 weeks. Its 52-week range is 18.75 EUR to 28.70 EUR: the price is 13.6% below the high and 32.3% above the low.

At a market capitalisation of 547.23M EUR, it trades at 38.8 times trailing earnings and 30.4 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, so LBIRD is valued in line with them. It pays a dividend yielding 1.54%, against a median of 0.73% among the dividend payers in that peer group.

Lumibird reports return on equity of 6.8%, an operating margin of 10.6% and revenue up 5.9% year over year.

Its debt exceeds its cash by 92.60M EUR, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock; their mean price target of 30.88 EUR is 24.5% above the current price.